Drug candidates for treatment identified
Research Highlights
Vast differences in SPG4 HSP explained
Disruption to another gene SARS2 identified
Predicting disease onset in SPG4 HSP
Particular features of gait identified
Promising gene therapy developed
Effective for DNM2 related diseases including SPG
Detailed study of SPG15 HSP
Comprehensive characterisation established
Calcium balance disrupted in SPG4 HSP
Relevant to disease mechanism
Clinical gait analysis tells HSP from CP
Machine learning the key
RNA technologies for neurodegenerative diseases
Advantages and challenges
SPG87 mechanism findings
Lipid processing, ER & mitochondria involved
New HSP genotypes and phenotypes
Research from USA, Germany, Brazil, UK, China, Taiwan, Iran, Azerbaijan, Pakistan